Dynamic Cardiac SPECT Imaging

Sponsor
University of California, San Francisco (Other)
Overall Status
Completed
CT.gov ID
NCT01934985
Collaborator
Lawrence Berkeley National Laboratory (LBNL) (Other), National Heart, Lung, and Blood Institute (NHLBI) (NIH)
83
1
122
0.7

Study Details

Study Description

Brief Summary

The investigators propose a 4 year prospective, observational study of 40 patients yearly, comparing conventional clinically indicated SPECT and PET perfusion with dynamic rest/stress MPI studies with coronary angiography, in some cases performed with quantitative coronary anatomy and flow as well as quantitative 13N-ammonia PET MPI. Methods will also be assessed for their ability to determine myocardial viability by comparing regional wall motion (WM) on clinically indicated serial ventriculography, echocardiography or gated SPECT MPI in those protocol patients with WM abnormalities who subsequently undergo revascularization. Patient studies will begin in the first study year based on those methods already developed and integrate new advances as they become evident.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    83 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Dynamic Cardiac SPECT Imaging
    Actual Study Start Date :
    Mar 1, 2012
    Actual Primary Completion Date :
    May 1, 2022
    Actual Study Completion Date :
    May 1, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Group 1

    Patients scheduled to have clinically indicated stress MPI with low pre-test likelihood (0-15%) of coronary disease based on criteria of Diamond and Forrester. And those who have already had a clinical indicated stress MPI in the last three years with a low likelihood of having active coronary disease with no significantly narrowed coronary arteries.

    Group II

    Patients in Group II who will have the dynamic imaging protocol studies after SCA, patients will be selected for protocol enlistment only if the decision is made by the patient's physician, based totally on clinical and social factors, that any considered revascularization intervention would not be performed on the day of diagnostic selective coronary angiography (SCA) and will be performed electively, at least 4 to 7 days later. Viability will be assessed in these patients only in the presence of WM abnormalities, and with serial analysis of WM, as described above. Patients will be followed for death or infarction or other events more than 3 months after study, for up to 3 years following participation in the protocol.

    Group III

    Patients found at SCA to have lesions of "borderline" clinical significance, preferably in the absence of other associated lesions.

    Group IV

    Patients who were diagnosed with advanced heart failure including patients who had or will have cardiac resynchonization therapy (CRT) or a heart transplant.

    Outcome Measures

    Primary Outcome Measures

    1. Coronary Flow Reserve [Length of procedure- 90 min]

      The coronary flow reserve will be measured by comparing the rest and stress exams on the dynamic SPECT scans using developed algorithms. The accuracy will be compared with clinical PET, coronary angiography, and clinical SPECT.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients who have had clinically indicated stress MPI with a low pre-test likelihood (0 - 15% ) of coronary disease based on the criteria of Diamond and Forrester.

    • Patients who have already had a clinically indicated stress MPI in the last three years with a low likelihood of having active coronary disease with no significantly narrowed coronary arteries.

    • Patients whose clinically indicated stress MPI demonstrates clear abnormalities and who are likely to go on to SCA for clinical indications.

    • If, after conventional and dynamic MPI some of these patients do not have SCA, they will still be followed for events for up to 3 years following participation in the protocol. To avoid delays and unnecessary procedures among patients in Group II who will have the dynamic imaging protocol studies after SCA, patients will be selected for protocol enlistment only if the decision is made by the patient's physician, based totally on clinical and social factors, that any considered revascularization intervention would not be performed on the day of diagnostic SCA and will be performed electively, at least 4 to 7 days later.

    • Patients found at SCA to have lesions of "borderline" clinical significance, preferably in the absence of other associated lesions.

    Exclusion Criteria:
    • Cannot give informed consent

    • Unable or unwilling to return for a second stress imaging study

    • Cannot cooperate for adequate SPECT or PET supine and/or prone imaging

    • Pregnant females

    • Patients under 21 years old

    • Active bronchospasm - No theophylline for 48 hours prior to study

    • Heart block more severe than Wenckebach block

    • Patients with uncomplicated infarction will not be included if they cannot have an exercise test later than 8 weeks of the event or a vasodilator pharmacologic stress test at least 24 hours or more after the event

    • Coronary bypass surgery within 8 weeks

    • Symptoms of congestive heart failure at rest

    • Has had an event or change in drug regimen since the initial stress test.

    • Has serious response to or side effect from initial clinical stress test induced ST elevation, hypotension, prolonged arrhythmia, bronchospasm.

    • Has had a clinical event since last coronary angiogram, angioplasty, or coronary surgery.

    • Has had 201Tl rest SPECT MPI prior to dynamic imaging

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of California, San Francisco Imaging Center San Francisco California United States 94107

    Sponsors and Collaborators

    • University of California, San Francisco
    • Lawrence Berkeley National Laboratory (LBNL)
    • National Heart, Lung, and Blood Institute (NHLBI)

    Investigators

    • Principal Investigator: Youngho Seo, Phd, University of California, San Francisco

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of California, San Francisco
    ClinicalTrials.gov Identifier:
    NCT01934985
    Other Study ID Numbers:
    • 5R01HL050663
    • 5R01HL050663
    First Posted:
    Sep 4, 2013
    Last Update Posted:
    Aug 9, 2022
    Last Verified:
    Aug 1, 2022

    Study Results

    No Results Posted as of Aug 9, 2022